Literature DB >> 28066559

Stereotactic body radiotherapy in the era of radiotherapy with immunotherapy.

Xiaolin Ge1, Hongcheng Zhu1, Wangshu Dai1, Xinchen Sun1.   

Abstract

Year:  2016        PMID： 28066559      PMCID： PMC5179427          DOI： 10.21037/jtd.2016.11.16

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  9 in total

Review 1.  Stereotactic body radiation therapy in non-small-cell lung cancer: linking radiobiological modeling and clinical outcome.

Authors:  Alexander Chi; Wolfgang A Tomé; Jack Fowler; Ritsuko Komaki; Nam P Nguyen; Minesh P Mehta; James S Welsh
Journal:  Am J Clin Oncol       Date:  2011-08       Impact factor: 2.339

2.  Maximizing tumor immunity with fractionated radiation.

Authors:  Dörthe Schaue; Josephine A Ratikan; Keisuke S Iwamoto; William H McBride
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-28       Impact factor: 7.038

3.  Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.

Authors:  Amit A Lugade; James P Moran; Scott A Gerber; Robert C Rose; John G Frelinger; Edith M Lord
Journal:  J Immunol       Date:  2005-06-15       Impact factor: 5.422

Review 4.  Radiotherapy combination opportunities leveraging immunity for the next oncology practice.

Authors:  Fernanda G Herrera; Jean Bourhis; George Coukos
Journal:  CA Cancer J Clin       Date:  2016-08-29       Impact factor: 508.702

Review 5.  Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

Authors:  Michael B Bernstein; Sunil Krishnan; James W Hodge; Joe Y Chang
Journal:  Nat Rev Clin Oncol       Date:  2016-03-08       Impact factor: 66.675

Review 6.  Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination?

Authors:  Mitchell Kamrava; Michael B Bernstein; Kevin Camphausen; James W Hodge
Journal:  Mol Biosyst       Date:  2009-08-27

7.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment.

Authors:  Youjin Lee; Sogyong L Auh; Yugang Wang; Byron Burnette; Yang Wang; Yuru Meng; Michael Beckett; Rohit Sharma; Robert Chin; Tony Tu; Ralph R Weichselbaum; Yang-Xin Fu
Journal:  Blood       Date:  2009-04-06       Impact factor: 22.113

8.  Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells.

Authors:  Molykutty J Aryankalayil; Adeola Y Makinde; Sofia R Gameiro; James W Hodge; Patricia P Rivera-Solis; Sanjeewani T Palayoor; Mansoor M Ahmed; C Norman Coleman
Journal:  Radiat Res       Date:  2014-07-08       Impact factor: 2.841

Review 9.  What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer.

Authors:  Alexander Chi; Sijin Wen; Zhongxing Liao; Jack Fowler; Jiahong Xu; Nam P Nguyen; James S Welsh; Ritsuko Komaki
Journal:  Biomed Res Int       Date:  2013-11-20       Impact factor: 3.411
  9 in total
  1 in total

Review 1.  Technological Advancements in External Beam Radiation Therapy (EBRT): An Indispensable Tool for Cancer Treatment.

Authors:  Krishna Koka; Amit Verma; Bilikere S Dwarakanath; Rao V L Papineni
Journal:  Cancer Manag Res       Date:  2022-04-11       Impact factor: 3.602
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.